New bladder cancer treatment aims to destroy tumors without removing the bladder
NCT ID NCT07260162
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This early-phase trial is testing a new drug called ATO-101 for people with a type of bladder cancer (non-muscle-invasive) that has come back after standard treatments like BCG therapy. The drug delivers a short-range radioactive particle directly to cancer cells in the bladder, aiming to destroy tumors while sparing healthy tissue. The main goal is to find the safest dose and see if it can control the disease, potentially offering a bladder-sparing option before more radical surgery is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, Loire Atlantique, 44800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.